Advertisement

Tumor Biology

, Volume 37, Issue 1, pp 1337–1340 | Cite as

The clinical utility of RFA in esophageal and cardia cancer patients with severe malignant obstruction

  • Hongxin Niu
  • Xikun Zhang
  • Bin Wang
  • Zhao Zhou
  • Jian Wang
  • Xiangshan Yang
  • Tong Du
Original Article

Abstract

Malignant obstruction of esophageal and cardia cancer greatly affects the prognosis and life quality of patients. However, no better regimens have been reported up to now. In recent years, radiofrequency ablation (RFA) has been prospectively proven in the management of some tumors. So, we investigated the impact of RFA on the malignant obstruction of esophageal and cardia cancer. In this study, we evaluated the operation duration, ablation duration, immediate compilations, etc., and followed up for 12 months. Our findings showed that there existed no technical problems in all 22 patients with a mean operation duration of 58 min and mean ablation duration of 23 min. No complication was observed in addition to postoperative low pressure in one patient and retrostenal pain in another patient. Importantly, all 22 patients obtained complete remission with normal diet and felt no sense of obstruction. Mean hospitalization time was 3 days and then the 12-month follow-up continued. To our relief, re-obstruction was not observed in all patients for 2 months. In conclusion, the entire effect of RFA was satisfactory, and patients can obtain a better life quality, less pains, and complications. So RFA should be advocated and greatly investigated by more institutes and hospitals.

Keywords

RFA Malignant obstruction Esophageal and cardia cancer 

Notes

Acknowledgments

This study is supported by the Shandong Province Science and Technology Development Project (No. 2014GSF118182). We are greatly thankful to the Department of Pathology in Affiliated Hospital of Shandong Academy of Medical Sciences and all members of Yang Lab.

Conflicts of interest

None

References

  1. 1.
    Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res. 2013;27(5):133–46.CrossRefGoogle Scholar
  2. 2.
    Radecke K, Gerken G, Treichel U. Impact of a self-expanding, plastic esophageal stent on various esophageal stenoses, fistulas, and leakages: a single-center experience in 39 patients. Gastrointest Endosc. 2005;61(7):812–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Larssen L, Medhus AW, Körner H, et al. Long-term outcome of palliative treatment with self-expanding metal stents for malignant obstructions of the GI tract. Scand J Gastroenterol. 2012;47(12):1505–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Manomaipiboon A, Wattanasirichaigoon S, Srisaovajate S, et al. Palliative esophageal stent or surgery in advanced esophageal malignancy. J Med Assoc Thai. 2001;84(10):1443–8.PubMedGoogle Scholar
  5. 5.
    Glazer ES, Massey KL, Zhu C, et al. Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. Surgery. 2010;148(2):319–24.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zacharoulis D, Khorsandi SE, Vavra P, et al. Pilot study for a new bipolar radiofrequency ablation/aspirator device in the management of primary and secondary liver cancers. Liver Int. 2009;29(6):824–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Eisele RM, Neuhaus P, Schumacher G. Radiofrequency ablation of liver tumors using a novel bipolar device. J Laparoendosc Adv Surg Tech A. 2008;18(6):857–63.CrossRefPubMedGoogle Scholar
  8. 8.
    Ueno S, Sakoda M, Kubo F, et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg. 2009;16(3):359–66.CrossRefPubMedGoogle Scholar
  9. 9.
    Leylek AM, Whitman GJ, Vilar VS, et al. Radiofrequency ablation for breast cancer. Tech Vasc Interv Radiol. 2010;16(4):269–76.CrossRefGoogle Scholar
  10. 10.
    Khorsandi SE, Zacharoulis D, Vavra P, et al. The modern use of radiofrequency energy in surgery, endoscopy and interventional radiology. Eur Surg. 2008;40(5):204–10.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Hongxin Niu
    • 1
  • Xikun Zhang
    • 1
  • Bin Wang
    • 1
  • Zhao Zhou
    • 1
  • Jian Wang
    • 1
  • Xiangshan Yang
    • 2
  • Tong Du
    • 1
  1. 1.Department of Minimally Invasive SurgeryAffiliated Hospital of Shandong Academy of Medical SciencesJinanPeople’s Republic of China
  2. 2.Department of PathologyAffiliated Hospital of Shandong Academy of Medical SciencesJinanChina

Personalised recommendations